1 story in the last 7 days
The latest besremi news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks besremi across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.
PharmaEssentia acquired FORUS Therapeutics for US$36.5 million, deepening its Canadian hematology-oncology presence. FORUS submitted a New Drug Submission for BESREMi in polycythemia vera in July 2025, with regulatory approval expected in Q3 2026. The deal fully integrates Canadian regulatory, medical, and commercial resources.
Summaries by ByteBrief